Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P43490

UPID:
NAMPT_HUMAN

ALTERNATIVE NAMES:
Pre-B-cell colony-enhancing factor 1; Visfatin

ALTERNATIVE UPACC:
P43490; A4D0Q9; A4D0R0; Q3KQV0; Q8WW95

BACKGROUND:
Nicotinamide phosphoribosyltransferase, alternatively named Pre-B-cell colony-enhancing factor 1 or Visfatin, is integral to NAD biosynthesis, serving as the rate-limiting enzyme in this pathway. It synthesizes nicotinamide mononucleotide, an essential precursor in NAD production. Apart from its enzymatic role, NAMPT functions as a cytokine and adipokine, offering immunomodulatory and anti-diabetic benefits. Additionally, it plays a significant role in circadian rhythm regulation by influencing NAD-dependent oscillations, which impacts the expression of core clock genes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Nicotinamide phosphoribosyltransferase presents a promising avenue for developing novel therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.